Das, A and Jawed, JJ and Das, MC and Praveen, S and Ghosh, C and Majumdar, S and Saha, B and Bhattacharjee, S (2020) Lupeol and amphotericin B mediate synergistic anti-leishmanialimmunomodulatory effects in Leishmania donovani-infected BALB/c mice.DKK4. Cytokine, 28 (137). p. 155319.

Full text not available from this repository. (Request a copy)

Abstract

Leishmania donovani, a protozoan parasite, inflicts the disease Visceral leishmaniasis (VL) Worldwide. The only orally bioavailable drug miltefosine is toxic, whereas liposomal amphotericin B (AmpB) is expensive. Lupeol, a triterpenoid from Sterculia villosa bark, was exhibited immunomodulatory and anti-leishmanial activity in experimental VL. Herein, we evaluated synergism between sub-optimum dose of AmpB and lupeol in anti-leishmanial and immunomodulatory effects in L. donovani-infected BALB/c mice. We observed that a combination of sub-optimum dose of lupeol and AmpB significantly reduced the hepatic and splenic parasitic burden accompanied by enhanced nitric oxide production, robust induction of Th1 cytokines (IL-12 and IFN-γ) but suppressed Th2 cytokine (IL-10 and TGF- β) production. The treatment with the lupeol-AmpB combination enhanced p38mitogen-activated protein kinase (p38MAPK), but reduced extracellular signal-related kinase (ERK-1/2), phosphorylation and up-regulated pro-inflammatory response. The present work thus indicates a lupeol-AmpB-mediated immunotherapeutic approach for eliminating the parasite-induced immunosuppression.

Item Type:	Article
Subjects:	Infection and Immunity
Depositing User:	Mr. Rameshwar Nema
Date Deposited:	18 Apr 2021 13:36
Last Modified:	18 Apr 2021 13:36
URI:	http://nccs.sciencecentral.in/id/eprint/914

Actions (login required)

View Item